Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Kroll · SciRah

Researcher profile · Semantic Scholar

S. Kroll

Share profile

S. Kroll — researcher profile on SciRah

h-index: 42
Works: 129
Citations: 7,642

Most-cited papers

131I-tositumomab therapy as initial treatment for follicular lymphoma.
M. Kaminski, M. Tuck, Judith M. Estes, A. Kolstad +7 more
2005New England Journal of Medicine725 citations Open access
Semantic Scholar
Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
M. Kaminski, A. Zelenetz, O. Press, M. Saleh +9 more
2001Journal of Clinical Oncology581 citations
Semantic Scholar
Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.
M. Kaminski, Judith M. Estes, K. Zasadny, Isaac R. Francis +9 more
2000Blood538 citations
Semantic Scholar
A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors
L. Raez, K. Papadopoulos, A. Ricart, E. Chiorean +11 more
2013Cancer Chemotherapy and Pharmacology524 citations
Semantic Scholar
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.
S. Horning, A. Younes, V. Jain, S. Kroll +3 more
2005Journal of Clinical Oncology267 citations
Semantic Scholar
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
W. Tap, Z. Pápai, B. Van Tine, S. Attia +24 more
2017The Lancet Oncology252 citations Open access
Semantic Scholar
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
R. Fisher, M. Kaminski, R. Wahl, S. Knox +6 more
2005Journal of Clinical Oncology251 citations
Semantic Scholar
Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients.
J. Armitage, P. Carbone, J. Connors, A. Levine +2 more
2003Journal of Clinical Oncology222 citations
Semantic Scholar
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
M. Borad, S. Reddy, N. Bahary, H. Uronis +13 more
2015Journal of Clinical Oncology186 citations Open access
Semantic Scholar
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
J. Leonard, M. Coleman, L. Kostakoglu, A. Chadburn +10 more
2005Journal of Clinical Oncology162 citations
Semantic Scholar
Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
J. Bennett, M. Kaminski, J. Leonard, J. Vose +7 more
2005Blood158 citations
Semantic Scholar
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
G. Weiss, J. Infante, E. Chiorean, M. Borad +11 more
2011Clinical Cancer Research147 citations Open access
Semantic Scholar
Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
S. Chawla, L. Cranmer, B. Van Tine, D. Reed +6 more
2014Journal of Clinical Oncology144 citations Open access
Semantic Scholar
The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy
T. Davis, M. Kaminski, J. Leonard, F. Hsu +8 more
2004Clinical Cancer Research144 citations Open access
Semantic Scholar
Ten-year follow-up of helium ion therapy for uveal melanoma.
D. Char, S. Kroll, J. Castro
1998American journal of ophthalmology-glaucoma120 citations
Semantic Scholar
Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation.
R. Wahl, S. Kroll, K. Zasadny
1998Journal of Nuclear Medicine119 citations
Semantic Scholar
Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
Andrew Davies, A. Rohatiner, Sacha Howell, K. Britton +16 more
2004Journal of Clinical Oncology106 citations
Semantic Scholar
Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience.
R. Wahl, K. Zasadny, David Macfarlane, I. Francis +6 more
1998Journal of Nuclear Medicine99 citations
Semantic Scholar
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
M. Kaminski, J. Radford, S. Gregory, J. Leonard +3 more
2005Journal of Clinical Oncology92 citations
Semantic Scholar
A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.
T. Ciuleanu, A. V. Pavlovsky, G. Bodoky, A. Garin +3 more
2009European Journal of Cancer81 citations
Semantic Scholar
A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
K. Ganjoo, L. Cranmer, J. Butrynski, D. Rushing +6 more
2011Oncology80 citations
Semantic Scholar
A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma.
S. Kroll, D. Char, J. Quivey, J. Castro
1998Ophthalmology (Rochester, Minn.)72 citations
Semantic Scholar
Randomized trial of radiation for age-related macular degeneration.
D. Char, Alexandra I. Irvine, M. Posner, J. Quivey +2 more
1999American journal of ophthalmology-glaucoma67 citations
Semantic Scholar
A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.
J. A. Siegel, S. Kroll, Denise D. Regan, M. Kaminski +1 more
2002Journal of Nuclear Medicine63 citations
Semantic Scholar
Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy.
D. Char, S. Kroll, T. Phillips, J. Quivey
2002Ophthalmology (Rochester, Minn.)59 citations
Semantic Scholar
A Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients with Advanced Leukemia
Talha Badar, D. Handisides, J. Benito, M. Richie +12 more
2016American journal of hematology/oncology39 citations Open access
Semantic Scholar
Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine‐131 tositumomab therapy
K. Koral, Isaac R. Francis, S. Kroll, K. Zasadny +2 more
2002Cancer35 citations Open access
Semantic Scholar
Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study
A. Brenner, R. Zuniga, Jessica D. Sun, J. Floyd +10 more
2018Neuro-Oncology33 citations Open access
Semantic Scholar
A Phase 1/2 Study of evofosfamide, A Hypoxia-Activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma
J. Laubach, Chia-Jen Liu, N. Raje, Andrew J. Yee +20 more
2018Clinical Cancer Research32 citations Open access
Semantic Scholar
Iodine I 131 Tositumomab for Patients With Follicular Non-Hodgkin’s Lymphoma (NHL): Overall Clinical Trial Experience by Histology
J. Vose, A. Zelenetz, A. Rohatiner, S. Knox +4 more
200022 citations
Semantic Scholar
A Phase 2 Trial of Glufosfamide in Combination With Gemcitabine in Chemotherapy-Naive Pancreatic Adenocarcinoma
E. Chiorean, T. Dragovich, J. Hamm, C. Barrios +6 more
2009American Journal of Clinical Oncology20 citations
Semantic Scholar
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma
E. Chiorean, T. Dragovich, J. Hamm, V. Langmuir +5 more
2008Cancer Chemotherapy and Pharmacology17 citations
Semantic Scholar
Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas
L. Raez, V. Langmuir, K. Tolba, C. Rocha-Lima +6 more
200717 citations
Semantic Scholar
Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021
W. Tap, Z. Pápai, B. Van Tine, S. Attia +16 more
201614 citations Open access
Semantic Scholar
Abstract LB-121: Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer
M. Borad, S. Reddy, H. Uronis, D. Sigal +12 more
201213 citations
Semantic Scholar
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
J. Mones, M. Coleman, L. Kostakoglu, R. Furman +8 more
2007Leukemia and Lymphoma12 citations
Semantic Scholar
Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane
J. O'Shaughnessy, L. Schwartzberg, M. Piccart, H. Rugo +32 more
202111 citations
Semantic Scholar
Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.
Stephen V. Liu, C. Aggarwal, Christina E. Brzezniak, R. Doebele +10 more
201611 citations
Semantic Scholar
Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL)
J. Leonard, M. Coleman, L. Kostakoglu, A. Chadburn +5 more
200410 citations
Semantic Scholar
Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL).
J. Leonard, M. Coleman, L. Kostakoglu, A. Chadburn +5 more
2004Journal of Clinical Oncology9 citations
Semantic Scholar
A dose-escalation study of tositumomab and iodine I 131 tositumomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with > 25% bone marrow involvement.
J. Mones, M. Coleman, L. Kostakoglu, J. Fiore +6 more
2004Journal of Clinical Oncology8 citations
Semantic Scholar
Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.
A. Seidman, L. Schwartzberg, Vinay K. Gudena, P. Rubin +4 more
20187 citations
Semantic Scholar
Phase I study of TH-302, a hypoxia-activated cytotoxic prodrug, in subjects with advanced leukemias.
M. Konopleva, D. Handisides, G. Lorente, J. Benito +9 more
20127 citations
Semantic Scholar
Final results of a phase I study of TH-302, a hypoxia-activated cytotoxic prodrug (HAP).
J. Bendell, G. Weiss, J. Infante, E. Chiorean +6 more
2009Journal of Clinical Oncology6 citations
Semantic Scholar
A randomized, blinded, parallel group, placebo controlled pilot study evaluating the effect of PVAC treatment in patients with diffuse systemic sclerosis.
M. Genovese, E. Chakravarty, D. Boyle, Z. Tutuncu +6 more
2005Journal of Rheumatology6 citations
Semantic Scholar
Iodine-131 Tositumomab For Patients With Small Lymphocytic Lymphoma (SLL): Overall Clinical Trial Experience
M. Kaminski, O. Press, T. Lister, N. Valente +2 more
20005 citations
Semantic Scholar
A Phase 1 Study of TH-302, an Investigational Hypoxia-Targeted Drug, in Patients with Advanced Leukemias
M. Konopleva, D. Handisides, M. Richie, J. Benito +8 more
20134 citations
Semantic Scholar
Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302
G. Weiss, K. Lewandowski, Jon Oneall, S. Kroll
2011Dermatology Reports4 citations Open access
Semantic Scholar
Phase I/II study of TH-302 combined with doxorubicin in soft tissue sarcoma.
L. Cranmer, S. Chawla, D. Rushing, J. Butrynski +6 more
20104 citations
Semantic Scholar
Tositumomab and Iodine I 131 Tositumomab (The BEXXAR® Therapeutic Regimen) Produced Ongoing, Durable Remissions of More Than 5 Years in 9 Patients with Non-Hodgkin’s Lymphoma (NHL) in a Pivotal Study of Patients Refractory to Their Last Chemotherapy.
M. Kaminski, A. Zelenetz, O. Press, M. Saleh +7 more
20044 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Kaminski×13
Invite
M. Kaminski — researcher profile on SciRah
J. Leonard×10
Invite
J. Leonard — researcher profile on SciRah
R. Wahl×9
Invite
R. Wahl — researcher profile on SciRah
V. Langmuir×9
Invite
V. Langmuir — researcher profile on SciRah

×7

Invite

S. Knox — researcher profile on SciRah

Invite

E. Chiorean — researcher profile on SciRah

Invite

M. Coleman — researcher profile on SciRah

Invite

A. Zelenetz — researcher profile on SciRah

S. Goldsmith×6

Invite

S. Goldsmith — researcher profile on SciRah

Invite

K. Zasadny — researcher profile on SciRah

Invite

G. Tidmarsh — researcher profile on SciRah

Invite

K. Ganjoo — researcher profile on SciRah